Ratings APT Medical Inc.

Equities

688617

CNE100004C45

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 03/12/2024			5-day change	1st Jan Change
373.50 ^CNY	+2.89%		+6.11%	+39.40%

10-25	APT Medical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
09-23	APT Medical Inc.(XSSC:688617) added to FTSE All-World Index	CI

Summary: APT Medical Inc.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Highlights: APT Medical Inc.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The group usually releases upbeat results with huge surprise rates.

Weaknesses: APT Medical Inc.

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 51.84 times its estimated earnings per share for the ongoing year.
The company appears highly valued given the size of its balance sheet.
The company is not the most generous with respect to shareholders' compensation.
Revenue estimates are regularly revised downwards for the current and coming years.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings Chart: APT Medical Inc.

Source: Surperformance

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
APT MEDICAL INC.		4.84B
PENUMBRA, INC.		9.4B
MASIMO CORPORATION	-	9.19B
ASAHI INTECC CO., LTD.		4.75B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.		4.73B
GETINGE AB		4.26B
NOVOCURE LIMITED	-	3.23B
INARI MEDICAL, INC.	-	3.05B
SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD		1.57B
Average		5B
Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes